Table 1 Clinicopathological features of the patients

n

62

17

45

Gender

female

18 (29%)

4 (23.5%)

14 (31.1%)

male

44 (71%)

13 (76.5%)

31 (68.9%)

Age at diagnosis

<60

30 (48.4%)

9 (52.9%)

21 (46.7%)

≥ 60

32 (51.6%)

8 (47.1%)

24 (53.3%)

Smoking history

yes

35 (56.5%)

12 (70.6%)

23 (51.1%)

no

27 (43.5%)

5 (29.4%)

22 (48.9%)

Stage at diagnosis

I

4 (6.5%)

1 (5.9%)

3 (6.7%)

II

2 (3.2%)

1 (5.9%)

1 (2.2%)

III

4 (6.5%)

3 (17.6%)

1 (2.2%)

IV

44 (71.0%)

10 (58.8%)

34 (75.6%)

Unknown

8 (12.9%)

2 (11.8%)

6 (13.3%)

Histology

Adenocarcinoma

57 (91.9%)

15 (88.2%)

42 (93.3%)

Squamous carcinoma

3 (4.8%)

2 (11.8%)

1 (2.2%)

Large cell carcinoma

2 (3.2%)

0 (0%)

2 (4.4%)

Diagnostic time interval

≤ 1 month

43 (69.4%)

10 (58.8%)

33 (73.3%)

> 1 month

19 (30.6%)

7 (41.2%)

12 (26.7%)

Brain tumor size (mm), median (IQR)

29.5 (22.125, 41.75)

28.0 (16.0, 33.0)

30.0 (23.0, 42.0)

Brain metastases number

Single brain metastases

39 (62.9%)

11 (64.7%)

28 (62.2%)

Multiple brain metastases

23 (37.1%)

6 (35.3%)

17 (37.8%)

Extracranial metastases

Yes

13 (21%)

4 (23.5%)

9 (20.0%)

No

49 (79%)

13 (76.5%)

36 (80.0%)

EGFR Mutation

Yes

13 (20.7%)

4(23.5%)

9 (20.0%)

No

14 (22.6%)

2(11.8%)

12 (26.7%)

Not tested

35 (56.5%)

11(64.7%)

24 (53.3%)

ALK rearranged

Yes

1(1.6%)

0 (0%)

1(2.2%)

No

16(25.8%)

4 (23.5%)

12 (26.7%)

Not tested

45 (72.6%)

13 (76.5%)

32(71.1%)

Treatment modality

SR

5 (8.1%)

2 (11.8%)

3 (6.7%)

SR + Rad/Chemo

18(29.0%)

7 (41.2%)

11 (24.4%)

SR + Rad/Chemo + TKIs

16(25.8%)

5 (29.4%)

11(24.4%)

Unknown

23(37.1%)

3 (17.6%)

20(44.4%)